Design and evaluation of potent peptide-mimetic PAR1 antagonists

Drug Development Research

Volumn 59, Issue 4, 2003, Pages 355-366

  Derian, Claudia K ^a   Maryanoff, Bruce E ^a   Andrade Gordon, Patricia ^a   Zhang, Han Cheng ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antithrombotic; Platelet; Protease; Protease activated; Restenosis; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; BMS 200261; FR 171113; G PROTEIN COUPLED RECEPTOR; PEPTIDE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 ANTAGONIST; RWJ 53052; RWJ 56110; RWJ 58259; SCH 73754; SCH 79797; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY INTIMA PROLIFERATION; BLOOD VESSEL INJURY; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; MOLECULAR MODEL; MONKEY; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN FAMILY; PROTEIN FUNCTION; RAT; RESTENOSIS; REVIEW; THROMBOSIS;

EID: 0041817678     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10304     Document Type: Review

References (46)

1. Ahn H-S, Chaekalamannil S. 2001. Nonpeptide thrombin receptor antagonists. Drugs Future 26:1065-1085.
2. Alin H-S, Arik L, Boykow G, Burnett DA, Caplen MA, Czarniecki M, Domalski MS, Foster C, Manna M, Stamford AW, Wu Y. 1999. Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorg Med Chem Lett 9:2073-2078.
3. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M. 2000. Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo [3,2-f]quinazoline-1,3-diamine (SCH79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60:1425-1434.
4. 1 antagonist development. Curr Med Chem 9:1229-1250.
5. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang H-C, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE White KB. 1999. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 96:12257-12262.
6. 1) attenuates vascular restenosis following balloon angioplasty in rats. J Pharmacol Exp Ther 298:34-42.
7. 1) antagonists. Bioorg Med Chem Lett 11:2691-2696.
8. 1), the first known protease-activated G-protein-coupled receptor. Adv Med Chem 4:245-271.
9. Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ Seiler SM. 1996. Development of potent thrombin receptor antagonist peptides. J Med Chem 39:4879-4887.
10. Ceruso MA, McComsey DF, Leo GC, Andrade-Gordon P, Addo MF, Scarborough RM, Oksenberg D Maryanoff BE. 1999. Thrombin receptor-activating peptides (TRAPs): Investigation of bioactive conformations via structure-activty, spectroscopic, and computational studies. Bioorg Med Chem 7:2353-2371.
11. Chackalamannil S. 2001. Thrombin receptor antagonists as novel therapeutic targets. Curr Opin Drug Discov Dev 4:417-427.
12. Chackalamannil S, Doller D, Eagen K, Czarniecki M, Alin HS, Foster CJ, Boykow G. 2001. Potent, low molecular weight thrombin receptor antagonists. Bioorg Med Chem Lett 11:2851-2853.
13. Chao BH, Kalkunte S, Maraganore JM, Stone SR. 1992. Essential groups in synthetic agonist peptides for activation of the platelet thrombin receptor. Biochemistry 31:6175-6178.
14. Cheung W-M, D'Andrea MR, Andrade-Gordon P, Damiano BP. 1999. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioseler Thromb Vase Biol 19:3014-3024.
15. Connolly TM, Condra C, Feng D-M, Cook JJ, Stranieri MT, Reilly CF, Nutt RF, Gould RJ. 1994. Species variability in platelet and other cellular responsiveness to thrombin receptor-derived peptides. Thromb Haemostasis 72:627-633.
16. Connolly AJ, Ishihara H, Kahn ML, Farese RV, Jr., Coughlin SR. 1996. Role of the thrombin receptor in development and evidence for a second receptor. Nature 381:516-519.
17. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos, A. 2002a. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99:643-648.
18. Covic L, Misra M, Badar J, Singh C, Kuliopulos, A. 2002b. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8:1161-1165.
19. Darrow AL, Fung-Leung WP, Ye RD, Santulli RJ, Cheung WM, Derian CK, Burns CL, Damiano BP, Zhou L, Keenan, CM, Peterson, PA, Andrade-Gordon, P. 1996. Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 76:860-866.
20. Derian CK, Santulli RJ, Tomko KA, Haertlein BJ, Andrade-Gordon P. 1995. Species differences in platelet responses to thrombin and SFLLRN. Receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases. Thromb Res 78:505-519.
21. Derian CK, Maryanoff BE, Zhang H-C, Andrade-Gordon P. 2003a. Therapeutic potential of protease-activated receptor-1 antagonists. Exp Opin Invest Drugs 12:209-221.
22. Derian CK, Damiano BP, Addo MF, Darrow AL, D'Andrea MR, Nedelman M, Zhang H-C, Maryanoff BE, Andrade-Gordon P. 2003b. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 304:855-861.
23. Feng D-M, Veber DF, Connolly TM, Condra C, Tang M-J, Nutt RF. 1995. Development of a potent thrombin receptor ligand. J Med Chem 38:4125-4130.
24. Guitteny A-F, Herbert J-M. 1997. Failure of heparin to inhibit the expression of the thrombin receptor following endothelial injury of the rabbit carotid artery. Eur J Pharmacol 327:157-162.
25. 1) antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif. Bioorg Med Chem Lett 8:1649-1654.
26. Hui KY, Jakubowski JA, Wyss VL, Angleton EL. 1992. Minimal sequence requirement of thrombin receptor agonist peptide. Biochem Biophys Res Commun 184:790-796.
27. Kato Y, Kita Y, Nishio M, Hirasawa Y, Ito K, Yamanaka T, Motoyama Y, Seki J. 1999. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol 384:197-202.
28. Major C, Santulli RJ, Derian CK, Andrade-Gordon P. 2003. Extracellular mediators in atherosclerosis and thrombosis: lessons learned from thrombin receptor knockout mice. Arterioscler Thromb Vase Biol 23:931-939.
29. 1). Curr Med Chem-Cardiovasc Hematol Agents 1:13-36.
30. 1). Bioorg Med Chem Lett 9:1423-1428.
31. 1) activation motif SFLLRN. Bioorg Med Chem Lett 9:255-260.
32. 1). Bioorg Med Chem Lett 12:319-323.
33. Natarajan S, Riexinger D, Peluso M, Seiler SM. 1995. Tethered ligand derived pentapeptide agonists of thrombin receptor: A study of side chain requirements for human platelet activation and GTPase stimulation. Int J Pept Protein Res 45:145-151.
34. Nelken NA, Soifer SJ, O'Keefe J, Vu TK, Charo IF, Coughlin SR. 1992. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 90:1614-1621.
35. Nose T, Shimohigashi Y, Ohno M, Costa T, Shimizu N, Ogino Y. 1993. Enhancement of thrombin receptor activation by thrombin receptor-derived heptapeptide with para-fluorophenylalanine in place of phenylalanine. Biochem Biophys Res Commun 193:694-699.
36. Ogletree ML, Natarajan S, Seiler SM. 1994. Thrombin receptors as drug discovery targets. Perspect Drug Disc Des 1:527-536.
37. Sabo T, Gurwitz D, Motola L, Brodt P, Barak R, Elhanaty E. 1992. Structure-activity studies of the thrombin receptor activating peptide. Biochem Biophys Res Commun 188:604-610.
38. Scarborough RM, Naughton MA, Teng W, Hung DT, Rose J, Vu TKH, Wheaton VI, Turck CW, Coughlin SR. 1992. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J Biol Chem 267:13146-13149.
39. + exchange by a thrombin receptor antagonist. Biochem Pharmacol 49:519-528.
40. Seiler SM, Peluso M, Tuttle JG, Pryor K, Klimas C, Matsueda GR, Bernatowicz MS. 1996. Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: Receptor-stimulated GTPase and evaluation of agonists and partial agonists. Mol Pharmacol 49:190-197.
41. Shimamoto T, Tsuboi H, Kitajima Y, Miyazaki T, Oyama Y, Imajo S, Ishiguro M. 1995. Modified thrombin receptor-agonist peptide ligands. Synthesis and conformational analysis of analogs of the N-terminal tripeptide region. Bioorg Med Chem Lett 5:2417-2422.
42. Smith KJ, Trayer IP, Grand RJA. 1994. Structure around the cleavage site in the thrombin receptor determined by NMR spectroscopy. Biochemistry 33:6063-6073.
43. Vassallo RR, Jr, Kieber-Emmons T, Cichowski K, Brass LF. 1992. Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem 267:6081-6085.
44. Wilcox JN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong C, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam, TA, Kelly, AB, Harker, LA, Runge, M. 1994. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res 75:1029-1038.
45. 1) antagonists. Solid-phase synthesis of indole-based peptide mimetics by anchoring to a secondary amide. Bioorg Med Chem Lett 11:2105-2109.
46. 1) antagonists: Potent, selective peptide mimetics based on indole and indazole templates. J Med Chem 44:1021-1024.